Sandoz CEO forecasts a Q1 or Q2 market entry for semaglutide biosimilars in Canada
Canada will be the first regulated market to undergo a market influx of semaglutide biosimilars.
Therapy Area
Modulight secures $12m to shine precise light on neurological diseases
FDA calls for black box warning to be removed from HRT products
AHA 2025: semaglutide 2.4mg lowers cardiovascular risk in SCORE-HF Study
Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer
Rhythm forced to wait for Imcivree expansion as FDA delays decision
Trump hits long-term pledge as US prices of weight loss drugs slashed
J&J’s Caplyta wins MDD approval to extend revenue horizon
